



Gallagher

Insurance | Risk Management | Consulting

SUMMER 2022

EMI

Employer Market
Intelligence

EMPLOYER MARKET TRENDS

A private ongoing, multiclient study.

Gallagher Research & Insights, St. Louis, MO 63131

© Gallagher Benefit Services, Inc.

All rights reserved. Published 2022

Printed in the United States of America

This Report is licensed only to the original party licensed by Gallagher Benefit Services, Inc. (respectively the "Licensee" and "Gallagher") and is subject to a binding license agreement between Licensee and Gallagher. Gallagher continues to retain title to and ownership of this Report. All copies and portions of this Report, in any form, belong to Gallagher, which retains all rights not expressly granted. Licensee is entitled to use this Report solely for its own internal business purposes and is prohibited from modifying, translating, or otherwise creating derivative works based on this Report. Licensee is further prohibited from licensing, selling, leasing, distributing, lending or otherwise transferring this Report to any third party. Licensee may not make any copies of Gallagher Reports except for internal distribution purposes as described and agreed to in the license agreement provided that all such copies are reproduced with and incorporate all of Gallagher's protective notices, including this and all copyright notices. Nothing in this Report and/or license agreement applicable thereto constitute a waiver of Gallagher's rights under United States Copyright law or any other law.

This information has been obtained from sources which Gallagher believes to be reliable but we do not guarantee the accuracy or completeness of this information.

Table of Contents

Introduction	6
Employer & Coalition Participant Panel	7
Why Employers?	9
Executive Summary	11
Employer Segmentation	18
Segmentation Overview	18
Segmentation Results & Placement	24
Employer Segmentation—Manufacturer Implications	28
Pharmacy Benefit Management Trends	29
Pharmacy Management Initiatives	29
Value-based Benefit or Insurance Design (VBBD/VBID) for Pharmacy Benefits	31
Employer Perspectives on Prescription Drug Management	32
Formularies & Exclusion List Modifications	33
Alternative Pharmacy Contracting Models	35
Pharmacy Benefit Management Trends Summary	38
Pharmacy Benefit Management Trends—Manufacturer Implications	39
Biologics & Biosimilars	40
Specialty Concerns & Management Initiatives	40
Copay Accumulator & Maximizer Programs—Background & Trends	44
Copay Accumulator Program—Employer Experience	47
Biosimilar Familiarity & Benefit Design	50
Biosimilars Impact on Specialty Spend	54
Biologics & Biosimilars Summary	56
Biologics & Biosimilars—Manufacturer Implications	57
Employee Health & Healthcare Management	58
Data Integration	58
Importance of Managing Diseases & Conditions	60
Mental Health Management	65
Technology & Telehealth	67
Obesity Management	69
Employer Worksite Clinics	71
Employer Worksite Clinic Services	73
Value-Focused Healthcare Management	76
Consumer-Directed Health Plans (CDHPs)	79
Health Savings Accounts (HSAs)	81
Employee Health & Healthcare Management Summary	83
Employee Health & Healthcare Management—Manufacturer Implications	85

Employer Health Coalitions	86
Employer Health Coalition Overview	86
Coalition Quality & Value Initiatives	89
Disease States of Focus & Member Services	91
Coalition Data Integration	94
Coalition Pharmacy Group Purchasing	96
Coalitions & Copay Accumulator Adjustment & Maximizer Programs	99
Disease State & Manufacturer Support of Interest	101
Employer Health Coalitions Summary	103
Employer Health Coalitions—Manufacturer Implications	104
APPENDIX	105

List of Figures

Figure 1	Overview of Employer Segments	18
Figure 2	Distribution of Employers by Quadrant	24
Figure 3	Employer Sample by Quadrant	24
Figure 4	Segmentation Placement of Research Participants	25
Figure 5	Segmentation Placement of Research Participants by Plot Point	26
Figure 6	Segmentation Summary	27
Figure 7	Proportion of Employers Increasing Employee Cost Share	30
Figure 8	Current & Planned Pharmacy Management Initiatives	30
Figure 9	Participation in a Group Rx Purchasing Collective	30
Figure 10	Employers with Value-Based Benefit/Insurance Design (VBBD/VBID) for Pharmacy Benefits	31
Figure 11	Employer Approach to VBBD/VBID for Pharmacy Benefits	31
Figure 12	Employer Perspectives on PBM's National Formulary & Exclusion Lists	32
Figure 13	Employer Approach to the National Prescription Drug List (PDL)	34
Figure 14	Top Reasons for Accepting the PBM's Formulary without Changes	34
Figure 15	Employers' Approach to Coverage of Drugs on their PBM's (or Health Plan's) Exclusion List	34
Figure 16	Description of Alternative Pharmacy Contracting Agreements	37
Figure 17	Current & Future Use of Alternative Pharmacy Contracting & Purchasing Models	37
Figure 18	Concerns Pertaining to Biologics/Specialty Rx	42
Figure 19	Initiatives to Manage Cost & Utilization of Biologics	42
Figure 20	Most Effective Employer Initiatives for Managing Cost of Biologics/Specialty Rx	43
Figure 21	Disease States for Which Employers Use a Biologics Preferred Drug List	43
Figure 22	Utilization of Copay Accumulator Adjustment Programs	46
Figure 23	Utilization of Copay Maximizer Programs	46
Figure 24	4-Year Trend: Employer Use of Copay Accumulator Adjustment Program (CAAP) & Copay Maximizer	46
Figure 25	Factors Impacting Employers' Decision to Implement Copay Accumulator Adjustment Programs	48
Figure 26	Drug Class for Which Copay Accumulator Adjustment Program is Applied	49
Figure 27	Reasons for Not Implementing Copay Accumulator Adjustment Programs	49
Figure 28	Impact of CAAPs on Outcomes	49
Figure 29	Employers' Self-Reported Knowledge of Biosimilars: 2020-2022	51
Figure 30	Top Sources for Biosimilar Information and Education, including Cost & Approvals/Pipeline	51
Figure 31	Agreement that Organization Received Sufficient Information to Make Informed Benefit Design Decisions for Biosimilars	53
Figure 32	Benefits Management Approaches in Place for Biosimilars	53
Figure 33	Expected Impact of Biosimilars on Total Specialty Drug Spend: 2017-2027	55
Figure 34	Greatest Barriers to Achieving Cost Savings with Biosimilars	55
Figure 35	Degree of Data Integration for Planning, Measurement and Management of Medical & Pharmacy Benefit Decision Making	59
Figure 36	Employer Approach to Data Integration	59
Figure 37	Degree to Which Organizations Use Data to Track and Measure the Impact of Health and Benefit Management Programs	59

Figure 38	Importance of Managing Disease States or Conditions to Employers	61
Figure 39	Top Disease States or Conditions Impacting Employee Productivity	63
Figure 40	Importance of Providing Employees with Information & Resources Related to Prevention & Screening	64
Figure 41	Channels through Which Employers Offer Mental/Behavioral Health Services	66
Figure 42	Satisfaction with Outcomes of Mental or Behavioral Health Services	66
Figure 43	Coverage of Technology-Driven Healthcare	68
Figure 44	Avenues for Offering Medical Telehealth	68
Figure 45	Employer Initiatives to Manage Obesity	70
Figure 46	Coverage of Branded Weight Loss Medications	70
Figure 47	Employer Worksite Health Clinics	72
Figure 48	Party Responsible for Running Worksite Clinic	72
Figure 49	Worksite Pharmacy Offerings	74
Figure 50	Services Offered at Worksite Clinics	75
Figure 51	Disease States/Conditions for Which Services, Initiatives, Education or Other Resources are Offered at Worksite Clinics	75
Figure 52	Value-Focused Health Benefit Management	78
Figure 53	Contracting Avenues for Value-Focused Initiatives	78
Figure 54	Employers Offering CDHPs	80
Figure 55	Employer Approach to CDHP Offerings (2017 to 2022)	80
Figure 56	Percentage of Total Covered Lives Enrolled in CDHPs	80
Figure 57	CDHP-HSA Pharmacy Coverage	82
Figure 58	Core Coalition Functions to Improve Local/Regional Healthcare	87
Figure 59	Guidelines for Coalition Tiers	87
Figure 60	Coalition Targets by Tier	88
Figure 61	Trends Gaining Traction in Coalitions' Local Healthcare Markets in 2022	90
Figure 62	Coalition Provision of Healthcare Quality & Cost Data, Tools & Information to Employer & Community Stakeholders	90
Figure 63	Value-Based Initiatives Actively Supported by Coalitions	90
Figure 64	Importance of Disease States or Conditions to Coalitions	92
Figure 65	Coalition Services Offered to Employer Members	93
Figure 66	Coalitions with a Data Warehouse to Collect, Integrate and/or Benchmark Employer Member Benefits Data	94
Figure 67	Elements Included in Data Warehouse	95
Figure 68	Degree to Which Coalition Integrates Data to Inform Employer Member Pharmacy and Medical Benefit Decision Making	95
Figure 69	Coalition Access to Regional/Community-level Health Claims or Population Health Database	95
Figure 70	Coalitions Offering Group Pharmacy Benefit Purchasing	97
Figure 71	Coalition Pharmacy Group Purchasing Snapshot	98
Figure 72	Use of Alternative Pharmacy Contracting Models Among Group Purchasing Coalitions	98
Figure 73	Coalition Perspectives on Copay Accumulator Adjustment Programs	100
Figure 74	Likelihood of Coalitions to Recommend Copay Accumulator Adjustment & Maximizer Programs to Employer Members	100
Figure 75	Top Coalition Disease States of Interest for Receiving Information & Support from Manufacturers	102
Figure 76	Coalition Interest in Manufacturer Support by Type	102

List of Appendix Figures

- Figure A1 Breakdown of Research Participants 107
- Figure A2 Segmentation Placement of Research Participants by Company Name. 108
- Figure A3 Employers' Health Benefits Insurance Strategies. 109
- Figure A4 Insurance Fee Comparison 109
- Figure A5 Employer Research Participants. 110
- Figure A6 Coalition Research Participants 111

EMI 2022

Employer Market Trends Report

Introduction

Gallagher Research & Insights' eighteenth annual Employer Market Trends report examines the role of jumbo employers in the ever-changing health benefits landscape. This report is a core deliverable within the Employer Market Intelligence (EMI) syndicated research service which monitors topics influencing benefit design actions and decision making with a focus on pharmacy management and its impact on biopharmaceutical manufacturers.

This primary research includes results from an online study of 97 jumbo employers (5,000+ employees) and 30 employer health coalitions. Interviews were conducted with 8 employer benefit executives and 3 health coalition leaders (see Figure A1).

This report is leveraged by biopharmaceutical, digital health and diagnostic companies to assess the employer market and formulate a strategic approach to product/service alignment. Each section covers data findings, year-over-year trends, verbatims that provide a first-hand perspective into employer and coalition viewpoints, and a set of manufacturer implications.

KEY REPORT TOPICS:

- Employer Segmentation
- Pharmacy Benefit Management & Trends
- Biologics & Biosimilars
- Employee Health & Healthcare Management
- Employer Health Coalitions (*Offerings, Interests, Group Rx Purchasing, etc.*)

NEW TOPICS IN THE 2022 TRENDS REPORT:

Jumbo Employers:

- Degree to which data is used to track and measure the impact of health programs
- Newly added diseases of importance, productivity impact, and onsite clinic focus:
 - Allergy, Anxiety, Pneumonia
 - Importance of providing information for: Recommended adult and pediatric vaccines/immunizations, preventive cancer screenings and mental health screenings
- Satisfaction with outcomes of mental/behavioral health services
- Top reasons for accepting the PBM's formulary without changes
- Use of newly added specialty pharmacy management tactics & related effectiveness for:
 - Second specialty tiers
 - Carve out of specialty from the PBM to a specialty Rx vendor
 - Alternative funding vendor that assists in finding available foundation dollars to lower member cost
 - Utilization/risk management carve-out vendors
- Factors influencing decision to implement a copay accumulator adjustment program
- Benefits coverage for technology-driven services:
 - Genomic or genetic testing
 - Medical telehealth
 - Telemental/behavioral health
 - Mental wellness apps
 - Prescription Digital Therapeutics (PDTs)
 - Diabetes disease management

Employer Health Coalitions:


- Degree to which organization integrates data to inform members' benefit decision making
- Newly added diseases of importance for member resources and interest in biopharma support:
 - Allergy, Anxiety, Pneumonia
- Traction in local market around strategies to manage specialty medications
- Offering of preventive care education for members (*e.g., recommended adult and pediatric vaccines/immunizations, preventive cancer screenings and mental health screenings*)

Contact Sarah Daley at 314-656-2384 or sarah_daley@ajg.com with questions or comments about this report or the EMI Service.


Employer Participant Panel

97 SURVEYS | 8 INTERVIEWS | 4.7 MILLION COVERED U.S. LIVES

PARTICIPANTS BY NUMBER OF U.S. EMPLOYEES



INDUSTRY




*Other includes: Construction, Energy, Engineering, Real Estate


EMPLOYER RESPONDENT ORGANIZATIONAL POSITION



GEOGRAPHICAL BREAKDOWN OF EMPLOYER HEADQUARTERS




PERCENT OF ACTIVE EMPLOYEES IN A UNION




Coalition Participant Panel

30 SURVEYS | 3 INTERVIEWS | 37.8 MILLION MEMBER LIVES



COALITION GROUP BENEFIT PURCHASING




COALITION RESPONDENT ORGANIZATIONAL POSITION



SCOPE OF COALITION MEMBERSHIP & ACTIVITY



GEOGRAPHICAL BREAKDOWN OF COALITION LOCATIONS



See Appendix Figures A5 and A6 for a full list of employer and coalition participants.

Employer Segmentation

SEGMENTATION OVERVIEW

Gallagher Research & Insights' Proprietary Segmentation Model is a Tool to Effectively Target Employers and Offer Resources of Value

Gallagher Research & Insights' (GRI) segmentation model was developed in recognition that employers vary widely in their benefit design activation and approach to decision making. This tool helps biopharma manufacturers invest their targeting, engagement and collaboration efforts with employers that are most willing to take action and have influence in the broader market. An effective employer engagement strategy should not be one-size-fits-all and instead account for the varying employer "personalities" classified in the segmentation model.

The model emphasizes two central dimensions of employer behavior:

- Willingness to take action to implement solutions (x-axis), and
- Level of strategy in decision making (y-axis)

Employer placement is determined by responses to a series of survey questions relevant to each axis.


The Most Activated Employers (x-axis)...

- Have independent processes for evaluating vendor partner recommendations
- Proactively seek out, create and implement novel approaches
- Employ sophisticated benefit management approaches, such as alternative pharmacy contracting, VBBD and a customized formulary

The Most Strategic Employers (y-axis)...

- Have a 3+ year strategy for managing health and health benefits
- Collect and use data from multiple programs (medical, pharmacy, wellness, disability, absence) in planning and evaluation
- Make evidence-based, data-driven decisions

Figure 1: Overview of Employer Segments



While Predominantly Applied to Generic Medications, a Growing Number of Employers are Applying VBBD to Brand and Specialty Medications

For the last five years, the portion of employers deploying value-based benefit design (VBBD) for medications that treat high cost, chronic conditions has remained relatively stable (30-34% since 2018). An additional and sizeable segment intend to implement VBBD within two years (+18 points by 2024). Most commonly, 61% of employers with VBBD in place have moved generic medications to the lowest formulary tier and 24% offer them for free.

Trends in application of VBBD for brand and specialty medications are particularly noteworthy. Moving branded products to a reduced tier (39%) or the lowest tier (9%) both increased (+7 and +3 points, respectively). Notably, 15% of employers offer certain specialty medications for free, more than double last year's results (+9 points). Also doubling in size is the percent of employers that have moved specialty medications to the lowest tier (6%, +3pts). These findings represent significant gains for employee access and adherence among a typically high cost category of medications.

Figure 10: Employers with Value-Based Benefit/ Insurance Design (VBBD/VBID) for Pharmacy Benefits






Figure 11: Employer Approach to VBBD/VBID for Pharmacy Benefits (among employers with VBBD/VBID for Rx in place)



Employers Offering Free Specialty Medications via their VBBD



“A major change we made in the last year is the movement to a \$0 copay for specialty medications. Our motivation is compliance and adherence.”

– Benefits Director, Employer

“We recently added a zero dollar copay for certain maintenance medications.”

– Benefits Director, Employer

“We reduced copays for certain diabetes, substance abuse and other medications to eliminate cost barriers and non-adherence.”

– Healthcare Director, Employer

Data is Vital to Measuring the ROI of Benefit Programs for More Than One-Quarter of Employers

Twenty-eight percent of respondents report significant use of data to track the impact of their benefit programs. In many cases this involves synchronization of data feeds from multiple vendors and point solution providers in addition to what their health plan and PBM are supplying. This segment of “significant use” employers are more likely to use a specialized data warehouse vendor (56% versus 46 % of total respondents).

Two-thirds of employers are using data to measure the effect of their programs to a moderate degree (67%). Just 5% report minimal use of data in determining their programs’ impact. Follow-up interviews reveal that these employers may be in the early stages of establishing a data warehouse, or are facing challenges such as a merger/acquisition, staffing shortages or barriers quantifying results due to a dispersed workforce.

“I’m getting daily feeds from CVS into a data warehouse. That’s traditionally unheard of. If you can get it monthly, you’re lucky. We also require that our smaller point solutions—diabetes and second opinion vendors—are also integrating data into the data warehouse so I can measure the effectiveness of our programs.”

– Senior Director, Employee Health, Employer

Figure 35: Degree of Data Integration for Planning, Measurement and Management of Medical & Pharmacy Benefit Decision Making




Figure 36: Employer Approach to Data Integration (select all that apply)





Figure 37: Degree to Which Organizations Use Data to Track and Measure the Impact of Health and Benefit Management Programs



Transparency and High Value Care are Top Priorities as Coalitions Facilitate and Advocate for Improved Quality of Care

The vast majority of coalitions report that price and/or quality transparency are gaining significant or moderate traction in their local market (93%, +4 percentage points from 2021). As such, approximately seven in ten actively promote quality data transparency (73%) and price and cost data transparency (67%). Efforts are wide ranging, and include synthesizing publicly available reports, generating new reports, educating employers and encouraging providers and health plan stakeholders to more openly share their cost and quality data.

“We have been generating reports at the hospital and physician levels on quality and cost (as data are available) of high-volume and high-cost procedures and conditions. We also provide a lot of education on value-based benefits and purchasing. However, it’s up to each employer to decide what they will do, if anything.”

– President and CEO, Coalition

Most Coalitions Report that Management of Specialty Medications is a Top Priority across their Local Market

Management of specialty spend is particularly challenging as employers balance rising treatment cost and utilization with the quality of life and potentially lifesaving benefit it can have on complex and serious medical conditions. In fact, 93% of coalitions report that related management strategies have garnered moderate or significant traction. New solutions, such as alternative funding and specialty carve-outs, are emerging and coalitions play an important role in making their members aware of the options and potential consequences—positive or negative.

Coalitions are Keenly Focused on Improving Healthcare Value and Providing Opportunities for Members to Engage in the Effort

Seven in ten (70%) coalitions support benefit design solutions that encourage employee use of high-value therapies and services, such as free or reduced cost medications or wrap around support. More than half (57%) are actively promoting the use of healthcare providers that deliver superior quality and value. This includes coalescing and disseminating cost and quality data, and providing education and solutions such as high performance narrow networks and Centers of Excellence. Relatedly, half are also offering payment reform solutions that reflect provider value, including upside/downside risk and shared savings within an episode of care.

“We are developing a clinically integrated network for purchase by employers in 2023. Primary care is the foundation, integrated with behavioral health and specialist referrals based on best-in-class with negotiated episodes of care.”

– Executive Director, Coalition

93%

of coalitions report that price and quality transparency is gaining significant or moderate traction in their local market.

See page 40 for more on employer specialty management strategies.

70%

of coalitions support benefit design solutions that encourage employee use of high-value therapies and services.



Gallagher

Insurance | Risk Management | Consulting

12444 Powerscourt Drive, Suite 500
St. Louis, MO 63131-3612

o 314.968.0011

f 314.968.1199

www.benfieldresearch.com